Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

34results about How to "Time-consume and expensive" patented technology

Line testing method and apparatus therefor

To facilitate the use of relatively high frequency data transmission services over a wireline communication resource originally deployed to support low frequency voice band services, an assessment of the wireline communication resource (50-52) is based on attenuation of high frequency test signals, of known original level, that are generated (18) injected into the wireline communication resource from a test point (12). A detector (60) at a potential point of service, e.g. at a customers' premises (14), detects an attenuated level of the test signals and generates a control signal (70, 82), such as a drive current, indicative of the attenuation caused by the wireline communication resource (50-52). The control signal (70, 82) is then indirectly communicated back to the test point (12) in a coded form, and preferably within a voice band transmission. The coded form may be realized as modulation of a power supply provided to the customers' premises by the wireline communication resource, or could be achieved by up-link frequency mixing. In its most basic form, the control signal causes fluctuation on a visual level indicator at the customers' premises and therefore relies on a customer providing a verbal or toned response to the test point as to the level of the visual indicator. Effective attenuation at high frequencies can then be assessed based upon analysis of information coded into the voice band signal and its direct relationship with the original level of the injected high frequency signals.
Owner:RPX CLEARINGHOUSE

Methods for identifying drug pharmacology and toxicology

The invention combines a microarray and cell-based screening strategy that enables rapid identification of possible mechanisms underpinning the pharmacology and toxicology of drug candidates. The methods of the invention identified unique properties relating to apoptosis and the anti-inflammatory response elicited by several peroxisome proliferator activated receptor gamma (PPARγ) ligands. The methods illustrate, for example, that PPARγ ligands that are safe and effective drugs (e.g., Actos, Avandia) either do not induce apoptosis or only modestly induce apoptosis. Conversely, PPARγ ligands that have failed clinical development (e.g., Ciglitazone; Day, C., Diabet. Med., 16: 179-192 (1999)) or that have been withdrawn from the market (e.g., Troglitazone (Rezulin)) due to hepatotoxicity are potent inducers of apoptosis. The methods of the invention also illustrate that suppression of gene expression and protein expression for several pro-inflammatory factors by some PPARγ ligands occurs as a consequence of apoptotic induction (i.e., apoptosis produces an anti-inflammatory response). The invention also provides biomarkers for cellular pathways and methods for stratifying patient groups according to their biomarker expression as well as biomarkers that discriminate safe and effective drugs from compounds that have acute toxicities. These biomarkers provide novel insights into the mechanism of action and toxicity for test compounds, including cell death, anti-inflammatory activity, hepatotoxicity, and carcinogenicity. The methods are highly scalable and have broad application from discovery to the clinic, including compound prioritization, predictive pharmacology and toxicology; mechanism of action studies; and prognostic and diagnostic biomarker discovery.
Owner:RIBONOMICS

Analyzing biological cell material based on different interactions between illumination light and cell components

It is described a device (100) for analyzing biological cell material (115). The device (100) comprises a light source arrangement (120), which is adapted for directing a first (131) and a second illumination light (132) towards the cell material (115), wherein the first (131) and the second (132) illumination light comprises a first and a second spectral radiation component, respectively. The device (100) further comprises a detector arrangement (170), which is adapted for receiving a first measurement light (151) based on a first interaction of the first illumination light (131) with the cell material (115) and a second measurement light (152) based on a second interaction of the second illumination light (152) with the cell material (115). Further, the device (100) comprises an evaluation unit (180), which is coupled the detector arrangement (170) and which is adapted to evaluate a first signal (171a) and a second signal (171b) being indicative for the first (151) and the second measurement light (151), respectively. The device (100) may be used for accomplishing ultraviolet DNA image cytometryin combination with autofluorescence measurements of NAD(P)H.
Owner:KONINKLIJKE PHILIPS ELECTRONICS NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products